Cytokine · 2025
Genetic polymorphisms of IFNL3 are associated with risk of immune checkpoint inhibitor-related pneumonitis in lung cancer patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Shengzu, Duan Zhihui, Zhang Kai, Lu Tao, Zheng Guanghua
Аннотация
BACKGROUND: Checkpoint inhibitor-related pneumonitis (CIP) is the most common fatal adverse reaction among lung cancer patients received immune checkpoint inhibitors (ICIs) therapy. IFN-λ3 has anti-tumor and immunomodulatory effects in lung cancer; however, little is known about the IFNL3 polymorphisms in CIP susceptible population.
METHODS: Five candidate IFNL3 polymorphisms were genotyped in 102 CIP and 626 non-CIP lung cancer patients, and the serum level of IFN-λ3 was detected by ELISA among the participants.
RESULTS: The minor allele rs12979860-T, rs12980275-G and rs8099917-G were correlated with 2.524, 3.158 and 3.932-fold raised risk of CIP, respectively (p < 0.001). Moreover, subgroup analysis according to tobacco use history showed that rs12980275 was correlated with CIP susceptibility in both subgroups, while rs12979860 and rs8099917 were associated with CIP in smokers (p < 0.005). Additionally, the serum concentration of IFN-λ3 in CIP group was obviously less than that in non-CIP group (p < 0.0001), and CIP patients with mutation genotypes of rs12979860, rs12980275 or rs8099917 had lower level of IFN-λ3 compared with those carriers with wild genotypes (p < 0.01).
CONCLUSION: IFNL3 rs129798060-TT, rs12980275-GG and rs8099917-GG genotypes were associated with lower serum level of IFN-λ3 and CIP susceptibility in lung cancer patients.
METHODS: Five candidate IFNL3 polymorphisms were genotyped in 102 CIP and 626 non-CIP lung cancer patients, and the serum level of IFN-λ3 was detected by ELISA among the participants.
RESULTS: The minor allele rs12979860-T, rs12980275-G and rs8099917-G were correlated with 2.524, 3.158 and 3.932-fold raised risk of CIP, respectively (p < 0.001). Moreover, subgroup analysis according to tobacco use history showed that rs12980275 was correlated with CIP susceptibility in both subgroups, while rs12979860 and rs8099917 were associated with CIP in smokers (p < 0.005). Additionally, the serum concentration of IFN-λ3 in CIP group was obviously less than that in non-CIP group (p < 0.0001), and CIP patients with mutation genotypes of rs12979860, rs12980275 or rs8099917 had lower level of IFN-λ3 compared with those carriers with wild genotypes (p < 0.01).
CONCLUSION: IFNL3 rs129798060-TT, rs12980275-GG and rs8099917-GG genotypes were associated with lower serum level of IFN-λ3 and CIP susceptibility in lung cancer patients.